Quarterly earnings reports matter a lot more for some companies than others. According to Wall Street analysts, investors should look beyond Bellicum Pharmaceuticals Inc BLCM’s first-quarter earnings miss and focus on its drug pipeline, which includes leading cancer treatment candidate BPX-501.
Jefferies’ Analysis
For Jefferies analyst Biren Amin, the biggest takeaway from Bellicum’s earnings report was that the pipeline is on-track.
“BLCM continues discussions with [the] FDA to determine U.S. regulatory pathway for BPX-501,” Amin noted in a new report.
“BLCM also maintained that BP-004 is on track with enrollment, which will drive potential filing in EU in mid-2018.”
Amin expects an update on BPX-501 by mid-2017.
Cantor Fitzgerald’s Take
Cantor Fitzgerald analyst Elemer Piros expects that update to come at the European Hematology Association meeting in June.
“In our view, the focus remains on emerging data from the Phase ½ study with BXP-501 in pediatric haplo-stem cell transplant patients,” Piros explained.
In addition, Piros is looking for protocol for pivotal trials of BPX-501 in the U.S. to be finalized by the end of 2017. Cantor expects Bellicum’s reported cash balance of $165 million to be plenty to get the company through the end of 2018.
Piros believes Bellicum’s modified T-cell cancer treatments could eventually open the door for blood stem cell transplantation for more than 13,000 U.S. patients.
Both Cantor Fitzgerald and Jefferies remain bullish on Belicum’s shares. Jefferies maintains…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
